US Apheresis Market

ID: MRFR/MED/16369-CR 86 Pages Nidhi Mandole Last Updated: September 15, 2026
Us Apheresis Service Market Research Report Market Research Report Information By service type (Donor/Automated Apheresis, Therapeutic Apheresis, and Stem Cell Collection and Processing), By Application (Neurological Disorders, Autoimmune Disorders, Hematologic Disorders, Oncology, Metabolic Toxicology Disorders, Infectious Diseases, Cardiovascular Disorders, and Others), By End User (Hospitals, Blood Banks, Specialty Clinics, Research Laboratories, and Biotechnology Pharmaceutical Companies) and by Region (North, South, Midwest, and West) โ€“Market Forecast Till 2035
US Apheresis Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)9.3%
2024 Market Size$ 252 Million
2025 Market Size$ 275.44 Million
2035 Market Size$ 670 Million
Key Players
Fresenius Kabi
Terumo BCT
Haemonetics Corporation
Grifols S.A.
Cellerant Therapeutics
Kawasumi Laboratories
Opportunities
  • Supportive Regulatory Environment
  • Advancements in Apheresis Technology
  • Growing Awareness of Apheresis Benefits
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Type (USD Million)
      1. 4.1.1 Therapeutic Apheresis
      2. 4.1.2 Donor Apheresis
      3. 4.1.3 Plasma Apheresis
      4. 4.1.4 Cell Apheresis
    2. 4.2 Pharmaceutical, BY Application (USD Million)
      1. 4.2.1 Renal Disorders
      2. 4.2.2 Neurological Disorders
      3. 4.2.3 Cancer Treatment
      4. 4.2.4 Autoimmune Disorders
    3. 4.3 Pharmaceutical, BY End User (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Blood Donation Centers
      3. 4.3.3 Research Laboratories
    4. 4.4 Pharmaceutical, BY Procedure Type (USD Million)
      1. 4.4.1 Manual Apheresis
      2. 4.4.2 Automated Apheresis
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Fresenius Kabi (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Terumo BCT (JP)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Haemonetics Corporation (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Grifols S.A. (ES)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Cellerant Therapeutics (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Kawasumi Laboratories (JP)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Asahi Kasei Medical (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Medtronic (IE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Blood Centers of America (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 US MARKET ANALYSIS BY PROCEDURE TYPE
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
      4. 7.2.4 BY PROCEDURE TYPE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Apheresis Market Segmentation

US Apheresis Market By Type (USD Million, 2025-2035)

  • Therapeutic Apheresis
  • Donor Apheresis
  • Plasma Apheresis
  • Cell Apheresis

US Apheresis Market By Application (USD Million, 2025-2035)

  • Renal Disorders
  • Neurological Disorders
  • Cancer Treatment
  • Autoimmune Disorders

US Apheresis Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Blood Donation Centers
  • Research Laboratories

US Apheresis Market By Procedure Type (USD Million, 2025-2035)

  • Manual Apheresis
  • Automated Apheresis
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.